SEC Form 4 · accession 0001209191-18-044790
GYRE THERAPEUTICS, INC. · GYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Fletcher Payne
Officer — Chief Financial Officer
Period of report
Jul 30, 2018
Accepted (ET)
Aug 1, 2018 · 5:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001124105
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $9.68 | Jul 30, 2018 | A | 25,000 | A | — | Jul 30, 2028 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1Award vests monthly over four (4) years starting June 13, 2018.